報價延遲最少15分鐘:2024/12/23 22:11 EST
|
|
|
|
|
||||||||||||
|
|
|
|
|
5.9 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-2.46/-2.83
|
|
企業價值
550.69M
|
| 資產負債 |
|
每股賬面淨值
6.01
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
11.76M
|
|
每股收益
0.09
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘：2024/12/23 22:11 EST
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| Verve Therapeutics Inc is a genetic medicines company pioneering a new approach to the care of cardiovascular disease, transforming treatment from chronic management to single-course gene editing medicines. The company's initial two programs target PCSK9 and ANGPTL3, genes that have been extensively validated as targets for lowering blood lipids such as low-density lipoprotein cholesterol, a root cause of cardiovascular disease. The company views its operations as and manages its business in one operating segment operating exclusively in the United States. |